We are working hard to achieve our long-term goal of providing improved treatment options to seriously ill cancer patients with a high unmet medical need. To that end, we have built an experienced team of entrepreneurs, scientists, and investors with an outstanding track record in the industry.
Pascal Schweizer holds a PhD in Business Administration from Technical University Berlin and an M.Sc. in Industrial Engineering from University of Karlsruhe.
Wolfgang Schwandner holds a diploma and a PhD degree in Biology from Technical University Munich and Ludwig Maximilians University Munich.
After joining the pharmaceutical industry, he held various leadership positions over the last > 10 years in Pharma/Biotech at Bristol-Myers Squibb, 4SC AG, BioNTech SE and CatalYm GmbH in Medical Affairs and Clinical Development with a special focus in (Immuno-)Oncology, gaining a broad range of experience in early and late-stage clinical development and building up a broad and robust network of internationally recognized key opinion leader in Oncology.
Frank holds a PhD in Medicine from University of Mainz.
Before joining Thermosome, Uwe Michaelis served as COO of ImevaX and has held several research and management positions of increasing responsibility at Medigene AG from 2004 – 2011. Prior to this, he was a co-founder and CSO of Munich Biotech AG and has held relevant R&D positions at Boehringer Mannheim (now Roche Diagnostics) for seven years.
He holds a PhD in Biology from Ludwig Maximilians University Munich and a diploma in Biology from the University of Regensburg.
Kerstin Pino Tossi holds a PhD in Biochemistry and a diploma in Biology from Ludwig Maximilians University Munich.
Before joining Thermosome, Katrin co-founded the biotech company ChromoTek and built it from scratch to successful exit. As VP Finance and Administration, her areas of responsibility covered finance, administration, HR, IT and logistics.
Katrin holds a PhD in Biology from the Ludwig-Maximilians-University (LMU) Munich and a Master of Business Administration from the Technical University of Munich (TUM).
Prior to co-founding Thermosome, he gained extensive experience in the academic sector, e.g., as Laboratory Head of the liposome research group at the University Hospital of Munich or Scientific Project Manager at Max Planck Innovation GmbH.
Martin Hossann holds a PhD and a diploma in Chemistry from the University of Kaiserslautern.
He holds a PhD in Biochemistry from the MPI for Biophysical Chemistry, Goettingen.
He started his career in the central pharmaceutical research unit of Hoechst AG and Hoechst-Marion-Roussel (HMR). In 1998, Jochen joined Axys Pharmaceuticals (now Celera) in San Francisco, where he served as VP for Medicinal Chemistry and Structural Biology. In 2001, Jochen joined Jerini AG in Berlin as Chief Scientific Officer and Head of R&D until Jerini was acquired by Shire in 2008. Since then, he co-founded Kosa Pharma, 3B Pharmaceuticals and, most recently, Pharvaris where he continues to serve as COO and CSO. He also is a board member for the Charité Research Organisation GmbH, Senior Advisor to Kurma Partners and was previously Senior Advisor to TVM Capital.
He studied Chemistry in Goettingen and Muenster and was a post-doc in the laboratory of Nobel Laureate E.J. Corey at Harvard University.
Franz-Robert holds deep expertise in corporate and business unit strategy development, as well as performance improvement and commercial review and valuation. Franz-Robert has applied his consulting expertise globally, having been part of Bain’s Boston office between 2003 and 2006.
Franz-Robert Klingan started his career at Hoechst AG (now Sanofi). He received a degree in Chemistry from the Technical University of Munich, where he also earned his doctorate.
He brings many years of experience in private equity and venture capital and is always looking for the most promising and most innovative technologies and start-ups in the life sciences sector; he is responsible for deal sourcing, due diligence and active portfolio management.
Cédric studied Pharmaceuticals and Economics in Zurich.
Clinical Advisory Board
He is involved in all institutional research activities on sarcoma, which include neoadjuvant therapies in extremity and retroperitoneal sarcomas, new targets for specific STS types, genomic characterization of DF and its impact in tumor progression, mechanisms of resistance to therapy in GIST. He is the Principal Investigator of several Italian and International trials on STS, DF and GIST.
He serves as member of the board of directors of the Italian Sarcoma Group, member of the board of directors of the European Society of Surgical Oncology 2020-2024; international representative on the executive council of the SSO 2021-2024; member of the Sarcoma Task Force of the European Society for Medical Oncology. He was chair of the EORTC Soft Tissue and Bone Sarcoma Group (2015-2017), president of the Connective Tissue Oncology Society (2016); president of the Italian Society of Surgical Oncology (2019-2021). He is member of the European Surgical Association, the American Society of Clinical Oncology and honorary member of the Polish Society of Surgical Oncology. He is one of the initiators of a global collaborative effort on retroperitoneal sarcoma (Trans-atlantic Australasian RetroPeritoneal Sarcoma Working Group, TARPSWG), which involves over 180 institutions worldwide. Dr. Gronchi has authored more than 500 scientific publications (Scopus HIndex 96), serves as Associate Editor of Annals of Surgical Oncology, Journal of Surgical Oncology, Critical Reviews in Oncology/Hematology, Therapeutics Advances in Medical Oncology; Updates in Surgery.